Novartis stock holds steady as 2025 sales and profit stay strong

Novartis stock (CH0012005267) is anchored by full-year 2025 net sales of USD 50.3 billion, core operating income of USD 19.5 billion, and diluted EPS of USD 5.68, giving the Swiss drugmaker a clear earnings base into 2026.

USD 50.3 billion sales base

Novartis reported 2025 net sales of USD 50.3 billion, up 12% at constant currency from 2024, while core operating income reached USD 19.5 billion, up 22% at constant currency. The same annual figures show core margin at 38.9% in 2025, compared with 35.7% a year earlier, which signals that the profit mix improved as revenue expanded.

That combination matters for Novartis stock because the market usually prices large-cap pharmaceuticals on the quality of earnings as much as on revenue growth. A 22% rise in core operating income against 12% sales growth is a cleaner sign of leverage than a top-line move alone.

Core EPS at USD 5.68

For 2025, Novartis posted diluted earnings per share of USD 5.68, while core diluted EPS came in at USD 8.02. The gap between reported and core profit remains important in a portfolio with heavy research and development spending, because it shows how much of the business is affected by non-core items.

The 2025 dividend was CHF 3.50 per share, and Novartis also reported net cash of USD 13.4 billion at 31 December 2025. For investors, that cash position and payout level are part of the same story: Novartis can fund research, distributions, and portfolio changes without relying on near-term financing pressure.

Margins still define the story

Novartis said 2025 free cash flow was USD 14.7 billion, compared with USD 13.2 billion in 2024. That 11% increase gives the company room to absorb patent churn and late-stage development costs while keeping capital returns visible.

The annual report also showed core operating margin at 38.9% in 2025, up from 35.7% in 2024. A margin gain of 3.2 percentage points in one year is the type of metric that tends to matter most in Swiss pharma, where scale, launches, and pricing discipline can quickly shift valuation sentiment.

Cosentyx remains important

Cosentyx remains one of the most important products in the portfolio, and the annual report groups it among the companys key growth drivers in immunology. Novartis also highlighted Entresto, Kisqali, and Kesimpta in its 2025 product mix, which shows that the group is still relying on a diversified set of therapies rather than a single franchise.

That diversification matters because it helps spread revenue risk across oncology, immunology, cardiovascular, and neuroscience categories. The 2025 numbers suggest the company is still balancing older products with newer launches while maintaining a high-margin base.

CHF 3.50 dividend support

Novartis stock last closed at a market value that should be read alongside the companys 2025 fundamentals, not in isolation. The stock is listed on SIX Swiss Exchange under NOVN, and the relevant context for the share price remains the combination of USD 50.3 billion in 2025 sales, USD 19.5 billion in core operating income, and USD 14.7 billion in free cash flow.

For a global healthcare name of this scale, the main question is not whether growth exists, but whether the 2025 margin and cash-flow profile can hold as the product mix evolves in 2026.